About - CVS :

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Employees - 300000, CEO - J. David Joyner, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): 2.44, Piotroski Score(max is 10): 7, Working Capital: $-11589000000, Total Assets: $252974000000, Retained Earnings: $63282000000, EBIT: 6565000000, Total Liabilities: $175337000000, Revenue: $407905000000

AryaFin Target Price - $248.2 - Current Price $ - Analyst Target Price $

Stats & Key Metrics
TickerCVS
Index
Curent Price
Change
Market Cap
Average Volume
Income
Sales
Book Value/Share
Cash/Share
Dividend Est
Dividend TTM
Dividend Ex-Date
Employees
Moving Avg 20days
Moving Avg 50days
Moving Avg 200days
Shares Outstanding
Earnings Date
Inst. Ownership
Key Ratios & Margins
Price/Earnings
Forwad P/E
PE Growth
Price/Sales
Price/Book
Price/Cash
Price/FCF
Quick Ratio
Current Ratio
Debt/Equity
Return on Assets
Return on Equity
Return on Investment
Gross Margin
Ops Margin
Profit Margin
RSI
BETA(β)
From 52week Low
From 52week High
Earnings & Valuation
EPS
EPS next Year
EPS next Qtr
EPS this Year
EPS next 5 Year
EPS past 5 Year
Sales past 5 Year
EPS Y/Y
Sales Y/Y
EPS Q/Q
Sales Q/Q
Sales Surprise
EPS Surprise
ATR(14)
Perf Week
Perf Month
Perf Quarter
Perf Year
Perf YTD
Target Price

AryaFin Engine© - An AI FinTech Venture - 2024-26 Disclaimer